Reports Q3 revenue $31.11M, consensus $26.47M. “We are thrilled with the progress made during this period. Guiding this progress is our three-pronged strategy for growth which is comprised of: maximizing our existing customer business, advancing programs currently within our late-stage development pipeline towards commercialization, and finally, winning impactful new business that will continue to fill our project pipeline – from early-stage work to commercial site transfers. We believe this strategy will allow us to reach our goals of achieving a 12+% revenue CAGR and increasing Adjusted EBITDA* margins to more than 25% over the mid-term, and the results we have seen to date support our optimism.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- Lifecore Biomedical Approves Key Proposals at Annual Meeting
- Lifecore signs agreement with leading global pharmaceutical company
- Lifecore, PolyPeptide collab to offer peptide manufacturing solution
- Lifecore Biomedical, Inc. (LFCR) Q1 Earnings Cheat Sheet
- Lifecore Biomedical Approves New Cash Incentive Plan